Artificial miRNAs targeting mutant huntingtin show preferential silencing in vitro and in vivo

Molecular Therapy Nucleic Acids

Volumn 4, Issue , 2015, Pages e234-

  Monteys, Alex Mas ^a   Wilson, Matthew J ^b   Boudreau, Ryan L ^b   Spengler, Ryan M ^b   Davidson, Beverly L ^a,c  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUNTINGTIN; MICRORNA;

3' UNTRANSLATED REGION; ALLELE; ANIMAL EXPERIMENT; ARTICLE; CAG REPEAT; CONTROLLED STUDY; EMBRYO; GENE LINKAGE DISEQUILIBRIUM; GENE SILENCING; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84926664315     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1038/mtna.2015.7     Document Type: Article

References (30)

1. Duyao, M, Ambrose, C, Myers, R, Novelletto, A, Persichetti, F, Frontali, M et al. (1993). Trinucleotide repeat length instability and age of onset in Huntington's disease. Nat Genet 4: 387-392.
2. Kremer, B, Goldberg, P, Andrew, SE, Theilmann, J, Telenius, H, Zeisler, J et al. (1994). A worldwide study of the Huntington's disease mutation. The sensitivity and specificity of measuring CAG repeats. N Engl J Med 330: 1401-1406.
3. Orr, HT and Zoghbi, HY (2007). Trinucleotide repeat disorders. Annu Rev Neurosci 30: 575-621.
4. Lee, JM, Ramos, EM, Lee, JH, Gillis, T, Mysore, JS, Hayden, MR et al.; PREDICTHD study of the Huntington Study Group (HSG); REGISTRY study of the European Huntington's Disease Network; HD-MAPS Study Group; COHORT study of the HSG. (2012). CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion. Neurology 78: 690-695.
5. Garriga-Canut, M, Agustín-Pavón, C, Herrmann, F, Sánchez, A, Dierssen, M, Fillat, C et al. (2012). Synthetic zinc finger repressors reduce mutant huntingtin expression in the brain of R6/2 mice. Proc Natl Acad Sci USA 109: E3136-E3145.
6. Kordasiewicz, HB, Stanek, LM, Wancewicz, EV, Mazur, C, McAlonis, MM, Pytel, KA et al. (2012). Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. Neuron 74: 1031-1044.
7. Harper, SQ, Staber, PD, He, X, Eliason, SL, Martins, IH, Mao, Q et al. (2005). RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc Natl Acad Sci USA 102: 5820-5825.
8. Drouet, V, Perrin, V, Hassig, R, Dufour, N, Auregan, G, Alves, S et al. (2009). Sustained effects of nonallele-specific Huntingtin silencing. Ann Neurol 65: 276-285.
9. Boudreau, RL, McBride, JL, Martins, I, Shen, S, Xing, Y, Carter, BJ et al. (2009). Nonallelespecific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice. Mol Ther 17: 1053-1063.
10. McBride, JL, Pitzer, MR, Boudreau, RL, Dufour, B, Hobbs, T, Ojeda, SR et al. (2011). Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington's disease. Mol Ther 19: 2152-2162.
11. Grondin, R, Kaytor, MD, Ai, Y, Nelson, PT, Thakker, DR, Heisel, J et al. (2012). Six-month partial suppression of Huntingtin is well tolerated in the adult rhesus striatum. Brain 135(Pt 4): 1197-1209.
12. Hu, J, Matsui, M, Gagnon, KT, Schwartz, JC, Gabillet, S, Arar, K et al. (2009). Allelespecific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs. Nat Biotechnol 27: 478-484.
13. Hu, J, Liu, J and Corey, DR (2010). Allele-selective inhibition of huntingtin expression by switching to an miRNA-like RNAi mechanism. Chem Biol 17: 1183-1188.
14. Schwarz, DS, Ding, H, Kennington, L, Moore, JT, Schelter, J, Burchard, J et al. (2006). Designing siRNA that distinguish between genes that differ by a single nucleotide. PLoS Genet 2: e140.
15. Skotte, NH, Southwell, AL, Østergaard, ME, Carroll, JB, Warby, SC, Doty, CN et al. (2014). Allele-specific suppression of mutant huntingtin using antisense oligonucleotides: providing a therapeutic option for all Huntington disease patients. PLoS One 9: e107434.
16. Southwell, AL, Skotte, NH, Kordasiewicz, HB, Østergaard, ME, Watt, AT, Carroll, JB et al. (2014). In vivo evaluation of candidate allele-specific mutant huntingtin gene silencing antisense oligonucleotides. Mol Ther 22: 2093-2106.
17. Carroll, JB, Warby, SC, Southwell, AL, Doty, CN, Greenlee, S, Skotte, N et al. (2011). Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene/allele-specific silencing of mutant huntingtin. Mol Ther 19: 2178-2185.
18. Fiszer, A, Mykowska, A and Krzyzosiak, WJ (2011). Inhibition of mutant huntingtin expression by RNA duplex targeting expanded CAG repeats. Nucleic Acids Res 39: 5578-5585.
19. Yu, D, Pendergraff, H, Liu, J, Kordasiewicz, HB, Cleveland, DW, Swayze, EE et al. (2012). Single-stranded RNAs use RNAi to potently and allele-selectively inhibit mutant huntingtin expression. Cell 150: 895-908.
20. Pfister, EL, Kennington, L, Straubhaar, J, Wagh, S, Liu, W, DiFiglia, M et al. (2009). Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients. Curr Biol 19: 774-778.
21. Liu, W, Kennington, LA, Rosas, HD, Hersch, S, Cha, JH, Zamore, PD et al. (2008). Linking SNPs to CAG repeat length in Huntington's disease patients. Nat Methods 5: 951-953.
22. McBride, JL, Boudreau, RL, Harper, SQ, Staber, PD, Monteys, AM, Martins, I et al. (2008). Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proc Natl Acad Sci USA 105: 5868-5873.
23. Boudreau, RL, Spengler, RM and Davidson, BL (2011). Rational design of therapeutic siRNAs: minimizing off-targeting potential to improve the safety of RNAi therapy for Huntington's disease. Mol Ther 19: 2169-2177.
24. Monteys, AM, Spengler, RM, Dufour, BD, Wilson, MS, Oakley, CK, Sowada, MJ et al. (2014). Single nucleotide seed modification restores in vivo tolerability of a toxic artificial miRNA sequence in the mouse brain. Nucleic Acids Res 42: 13315-13327.
25. Boudreau, RL, Monteys, AM and Davidson, BL (2008). Minimizing variables among hairpin-based RNAi vectors reveals the potency of shRNAs. RNA 14: 1834-1844.
26. Nakanishi, K, Weinberg, DE, Bartel, DP and Patel, DJ (2012). Structure of yeast Argonaute with guide RNA. Nature 486: 368-374.
27. Doench, JG and Sharp, PA (2004). Specificity of microRNA target selection in translational repression. Genes Dev 18: 504-511.
28. Lewis, BP, Burge, CB and Bartel, DP (2005). Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120: 15-20.
29. Gray, M, Shirasaki, DI, Cepeda, C, André, VM, Wilburn, B, Lu, XH et al. (2008). Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J Neurosci 28: 6182-6195.
30. Boudreau, RL and Davidson, BL (2012). Generation of hairpin-based RNAi vectors for biological and therapeutic application. Methods Enzymol 507: 275-296.